Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.
Aged
Bone Density
/ drug effects
Bone Density Conservation Agents
/ administration & dosage
Bone Resorption
/ chemically induced
Denosumab
/ administration & dosage
Female
Follow-Up Studies
Fractures, Multiple
/ chemically induced
Humans
Male
Middle Aged
Osteoporosis
/ drug therapy
Prognosis
Substance Withdrawal Syndrome
/ diagnosis
Withholding Treatment
/ statistics & numerical data
denosumab
extracellular matrix
osteoblasts
osteoclasts
osteocytes
osteoporosis treatment
rebound fractures
treatment discontinuation
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
12
2019
accepted:
06
04
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
27
5
2021
Statut:
epublish
Résumé
Denosumab is a potent osteoclast inhibitor targeted to prevent osteoporotic bone loss and thereby reduce fractures in the aging population. Recently, an elevated risk of rebound fractures following denosumab discontinuation was identified, unless patients were transitioned to an alternative antiresorptive medication. How denosumab affects the interaction of mechanosensitive osteocytes and bone quality remains unknown. We hypothesized that denosumab influences osteocyte function contributing to bone reorganization and increased fractures during discontinuation. Bone quality and osteocytes were assessed in archived iliac crest bone biopsies obtained from patients with high fracture occurrence from 2011 to 2016. Biopsies were obtained due to high fracture occurrence prior and during osteoporosis therapy from (i) patients with at least two semiannual subcutaneous injections of 60 mg denosumab, (ii) patients with rebound fractures during discontinuation, and (iii) patients of a treatment-naive group. In total, biopsies from 43 individuals were analyzed (mean age, 65.5 ± 12.1 years). Our results showed that during denosumab treatment, iliac cortical bone had a higher bone tissue hardness compared to treatment-naive bone (
Identifiants
pubmed: 32499755
doi: 10.3389/fendo.2020.00250
pmc: PMC7243474
doi:
Substances chimiques
Bone Density Conservation Agents
0
Denosumab
4EQZ6YO2HI
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
250Informations de copyright
Copyright © 2020 Jähn-Rickert, Wölfel, Jobke, Riedel, Hellmich, Werner, McDonald and Busse.
Références
J Orthop Trauma. 2018 Sep;32(9):480-490
pubmed: 30036208
J Bone Miner Res. 2010 Oct;25(10):2256-65
pubmed: 20533525
J Bone Miner Res. 2013 Jan;28(1):2-17
pubmed: 23197339
N Engl J Med. 2006 Feb 23;354(8):821-31
pubmed: 16495394
Am J Med. 2000 Feb;108(2):153-64
pubmed: 11126309
Osteoporos Int. 2017 May;28(5):1723-1732
pubmed: 28144701
Biomaterials. 2015 Mar;45:46-55
pubmed: 25662494
Osteoporos Int. 2006;17(9):1404-9
pubmed: 16699736
Curr Osteoporos Rep. 2019 Jun;17(3):105-115
pubmed: 30980284
Bonekey Rep. 2015 Sep 02;4:743
pubmed: 26380080
J Exp Med. 2004 Mar 15;199(6):805-14
pubmed: 15024046
J Bone Miner Res. 2017 Jul;32(7):1391-1394
pubmed: 28556236
J Bone Miner Res. 2012 Jan;27(1):211-8
pubmed: 21976367
J Cell Biochem. 1994 Jul;55(3):273-86
pubmed: 7962158
Bone. 2011 Apr 1;48(4):677-92
pubmed: 21145999
P T. 2018 Feb;43(2):92-104
pubmed: 29386866
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
Bone. 2017 Dec;105:11-17
pubmed: 28789921
Curr Opin Pharmacol. 2016 Jun;28:24-30
pubmed: 26927500
J Bone Miner Res. 2011 Nov;26(11):2737-44
pubmed: 21735475
J Clin Endocrinol Metab. 2011 Apr;96(4):972-80
pubmed: 21289258
Osteoporos Int. 2016 May;27(5):1917-21
pubmed: 26694598
Sci Transl Med. 2013 Jul 10;5(193):193ra88
pubmed: 23843449
ACS Nano. 2013 Sep 24;7(9):7542-51
pubmed: 23909715
Small. 2017 Jan;13(3):
pubmed: 28084694
Bone. 2012 May;50(5):1115-22
pubmed: 22342796
N Engl J Med. 2009 Aug 20;361(8):756-65
pubmed: 19671655
Osteoporos Int. 2016 May;27(5):1677-82
pubmed: 26932443
Clin Cases Miner Bone Metab. 2007 May;4(2):108-16
pubmed: 22461210
J Bone Miner Res. 2020 Jan 30;:
pubmed: 31999373
Sci Rep. 2016 Feb 16;6:21072
pubmed: 26879146
Osteoporos Int. 2016 May;27(5):1929-30
pubmed: 26694593
Endocrinol Metab Clin North Am. 2005 Dec;34(4):1015-30, xi
pubmed: 16310636
J Clin Endocrinol Metab. 2017 Feb 1;102(2):354-358
pubmed: 27732330
Osteoporos Int. 2016 May;27(5):1923-5
pubmed: 26510845
Endocr Connect. 2020 Mar 1;:
pubmed: 32168472
J Bone Miner Res. 2015 Feb;30(2):264-73
pubmed: 25112610
Calcif Tissue Int. 2018 Mar;102(3):368-372
pubmed: 29103161
Nat Med. 2011 Sep 11;17(10):1231-4
pubmed: 21909105
Curr Osteoporos Rep. 2017 Dec;15(6):532-541
pubmed: 28956252
Aging Cell. 2010 Dec;9(6):1065-75
pubmed: 20874757
J Clin Endocrinol Metab. 2018 Jul 1;103(7):2498-2509
pubmed: 29672714
Calcif Tissue Int. 2018 Jul;103(1):109-110
pubmed: 29318330